Revive Appoints Infectious Disease Expert As Scientific Adviser

Revive Therapeutics (CSE: RVV) this morning announced that they have appointed Dr David Boulware as scientific advisor, aimed at assisting the company with its previously announced work on infectious diseases.

Boulware is expected to guide Revive on its current and future clinical programs, which includes the research and development strategy for infectious diseases. Boulware is an infectious disease physician-scientist, and is notably the principal investigator of a COVID-19 clinical trial that is looking at hydroxychloroquine and its post-exposure effects on coronavirus (ClinicalTrials.gov Identifier: NCT04308668).

Currently Professor of Medicine, Division of Infectious Diseases and International Medicine at The University of Minnesota, Boulware is primarily focused on meningitis, with his latest research involving improving the clinical outcomes of HIV-infected persons with cryptococcal meningitis and TB meningitis. Currently, Boulware serves on the United Nations and World Health Organization’s health panels for cryptococcal meningitis, as well as the WHO’s panel for advanced HIV disease.

I am excited to assist Revive in their objective in pursuing the clinical development of Bucillamine for infectious diseases and its prospect as a potential solution for COVID-19.

Dr. David Boulware, MD, MPH, CTropMed, FIDSA

Revive Therapeutics previously announced that it is exploring the use of Bucillamine as a potential treatment for infectious diseases, and that is has filed for a provisional patent in the US entitled “Use of Bucillamine in the Treatment of Infectious Diseases” (Serial No. 62/991,996).

Revive Therapeutics last traded at $0.08 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

How to Still Find 10-Bagger Gold and Silver Stocks | Don Durrett

First Majestic Silver: Jerritt Canyon Is BACK!

Canada May Finally Be Backing Its Battery Supply Chain | John Passalacqua – First Phosphate

Recommended

Questcorp’s La Union Surface Program Delivers 20 g/t Gold Over 2.9 Metres In Channel Sample

Kirkland Lake Discoveries Drills 39.35 g/t Gold Over 16.4 Metres As Mirado Continues To Grow

Related News

Rebound in Oil Demand Remains at Risk of Coronavirus Resurgence

As the global demand for oil dried up significantly during the height of the pandemic,...

Sunday, July 12, 2020, 07:17:00 PM

Hyperinflation: Remember, GDP = Money Supply x Velocity

When trying to wrap my head around economics, I like to simplify basic principles down...

Saturday, April 4, 2020, 01:45:58 PM

Revive Therapeutics To Expand Clinical Sites For Covid-19 Related Phase 3 Study

Revive Therapeutics (CSE: RVV) this morning provided an update on the status of its phase...

Friday, February 26, 2021, 08:54:19 AM

Canada Mortgage and Housing Corp: House Prices To Decline 9 – 18%

The Canadian Mortgage and Housing Corporation (CMHC) has recently issued an update regarding its ongoing...

Wednesday, May 20, 2020, 06:00:00 PM

Goldman Sachs Forecats Q2 GDP Crashing 34% in US w/ 15% Unemployment

This morning Goldman Sachs released a new forecast for Q3 US GDP and showing a...

Tuesday, March 31, 2020, 10:16:07 AM